Can low-dose propranolol induce a manic syndrome? Case report of an unexpected side effect

2013 ◽  
Vol 25 (3) ◽  
pp. 184-186 ◽  
Author(s):  
Mahin Eslami Shahrbabaki ◽  
Fariborz Estilaee ◽  
Amir Eslami Shahrbabaki

ObjectivesPropranolol, the first discovered b-adrenergic receptor antagonist, has been prescribed by physicians in various fields for more than three decades. It has been applied for treating psychiatric disorders including schizophrenia, mania and anxiety disorders, as well as for controlling withdrawal symptoms or other side effects.MethodsWe describe the case of an 11-year-old boy with bipolar-I disorder comorbid with panic disorder who developed manic symptoms with a single dose of 10 mg of propranolol.Results and ConclusionAlthough depression is a better-known side effect of b-adrenergic antagonists, clinicians should take mania as a rare side effect into consideration as well.

Author(s):  
Shalini Upadhyay ◽  
Prabhat Agrawal ◽  
Manish Bansal ◽  
Anjalika Gupta

ABSTRACTRifaximin is one of the common drugs used in clinical practice in the management of traveler’s diarrhea, irritable bowel syndrome (IBS), and hepaticencephalopathy. Hyponatremia is one of the rare side effects of this drug. We hereby present the case of a middle-aged woman who was a known caseof IBS: Diarrhea predominant who developed symptoms of hyponatremia after a short duration of rifaximin treatment, no other cause of hyponatremiawas found on evaluation, so we suspect this as a rare side effect of rifaximin therapy.Keywords: Rifaximin, Hyponatremia, Irritable bowel syndrome.


2021 ◽  
pp. 878-883
Author(s):  
Neethi Dasu ◽  
Yaser Khalid ◽  
Kirti Dasu ◽  
Lucy Joo ◽  
Brian Blair

Kayexalate has been used in the USA since 1975 for the treatment of hyperkalemia. Prior case reports have shown that sorbitol added to kayexalate has been known to cause rare side effects of colonic necrosis. We present a unique case report of gastric pneumatosis as a complication of kayexalate.


2020 ◽  
Vol 33 (4) ◽  
pp. e100203
Author(s):  
Arpita Thakur ◽  
Vijay Niranjan ◽  
Pali Rastogi ◽  
Ramghulam Razdan

Risperidone acts by potent serotonergic, dopaminergic and alpha adrenergic receptor antagonism. The most common side effects reported are extrapyramidal symptoms, dizziness, sedation, insomnia, headache, anxiety, nausea, constipation and weight gain. Oedema associated with risperidone use is a rare side effect. Here we present a report on pedal oedema associated with use of oral risperidone 4 mg per day for acute-onset psychotic illness. Through this case report we want to make clinicians aware about this important side effect as it can affect patients’ compliance and quality of life.


2021 ◽  
Vol 9 (C) ◽  
pp. 239-242
Author(s):  
Siti Salima ◽  
Ali Budi Harsono ◽  
Aisyah Aisyah ◽  
Kemala Mantilidewi

BACKGROUND: One of the harshest side effects following anticancer agent treatments is chemotherapy-induced neuropathic pain. After surgical staging, chemotherapy combination of paclitaxel carboplatin could be a choice of therapy for Stage II or more advanced stage of ovarian cancer. Different side effects may appear after the application of paclitaxel. CASE REPORT: Here, we show an uncommon case of paclitaxel-acute pain syndrome (P-APS), and how we deal with such cases according to our experiences. One uncommon side effect is P-APS, which can be treated effectively with the administration of non-steroidal anti-inflammatory drugs, corticosteroid, and supportive therapy. CONCLUSION: One uncommon side effect of Paclitaxel induced neuropathic can be treated effectively with the administration of non-steroidal anti inflammatory drugs, corticosteroid, and supportive therapy.


Author(s):  
A. O. Salako ◽  
S. O. Ogunmefun ◽  
O. W. Aworanti

Background: Hydroxyurea (HU) has redefined the quality of life of children with sickle cell anaemia and their care givers. Despite the acclaimed benefits of HU, the drug could be associated with variable side effects affecting different systems in the human body, including the skin and integuments. The aim of this report is to raise the awareness about the less common side effects of HU. Case Report: A 5-year 8 months old homozygous sickle cell anaemia child presented with pruritic hyperpigmented lesions on the trunk, arms and the legs, four weeks after commencement of HU. HU was initially discontinued for two weeks and thereafter recommenced with a different brand but there was worsening skin lesions despite at a daily low dose of 10 mg/kg. The rashes eventually resolved with low dose once in 3 days HU therapy.  She had recurrent episodes of acute painful crisis; average of three [3] episodes per year warranted hospital admission prior to commencement, but with HU therapy, there has been significant improvement in the crisis. Discussion: Cutaneous lesions are uncommon side effect of hydroxyurea. This side effect is dependent on genetic predisposition and photosensitivity. However, with the established benefit of HU in the management sickle cell anaemia, it is important for the sickle cell experts to continue to monitor closely the children for both the common and rare side effects and to individualize therapy to ensure maximal benefit with minimal or no side effects.


2020 ◽  
Vol 7 (3) ◽  
pp. 69-72
Author(s):  
Sonia Amin Thomas ◽  
Harnisha Patel

A 41-year-old patient with Metastatic Breast Cancer suffered from pneumonitis after administration of cyclophosphamide. A CT angiogram with IV contrast was compatible with bronchopneumonia and it was treated with broad spectrum antibiotics. Other causes of pulmonary disease were ruled out concluding patient developed cyclophosphamide induced pneumonitis. Thus, more attention is required to the serious and rare side effects of cyclophosphamide related lung toxicities. In this case report, we will focus on the rare side effects such as cyclophosphamide-induced pneumonitis (AIP) occurring in less than 1% of the population.


Vaccines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1486
Author(s):  
Po-Wei Liao ◽  
Chieh-Lin Jerry Teng ◽  
Cheng-Wei Chou

We present a case of immune thrombocytopenia (ITP) induced by the chimpanzee adenovirus-vectored vaccine, without evidence of thrombosis, eight days after vaccine administration. The thrombocytopenia condition improved after administering steroid treatment. This adenovirus vaccine had been reported to induce rare side effects, such as immune thrombotic thrombocytopenia. This case report showed that it could also induce immune thrombocytopenia without the presence of thrombosis. Therefore, we should be cautious of this rare side effect as global vaccine administrations against coronavirus disease increase.


Sign in / Sign up

Export Citation Format

Share Document